美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

F/m Emerald Life Sciences Innovation ETF

46.07

+0.69411.53%

成交量：1,225

成交額：5.65萬

市值：1.27億

市盈率：- -

高：46.36

開：46.10

低：46.07

收：45.37

52周最高：48.78

52周最低：27.80

股本：275.70萬

流通股本：275.70萬

量比：0.53

換手率：0.04%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Cogent Biosciences宣佈FDA受理Bezuclastinib治療晚期系統性肥大細胞增多症的新藥申請

Guardant Health與Evernorth旗下Evicore達成協議，Shield血液檢測自2027年1月1日起納入結直腸癌篩查覆蓋範圍

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

Spyre Therapeutics旗下Spy003療法在第12周實現20%臨床緩解率及30%內鏡改善率

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/LFSC"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":46.065,"timestamp":1789668490925,"preClose":45.3709,"halted":0,"volume":1225,"delay":0,"changeRate":0.015298352027400798,"floatShares":2757035,"shares":2757035,"eps":0,"marketStatus":"交易中","change":0.6941,"latestTime":"09-17 14:09:18 EDT","open":46.095,"high":46.3649,"low":46.065,"amount":56459.866575,"amplitude":0.00661,"askPrice":46.03,"askSize":200,"bidPrice":45.83,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":45.3709,"sharesOutstanding":2657035,"nav":45.36,"aum":125059107.6,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":45.335,"preClose":45.3709,"latestTime":"16:15 EDT","volume":10,"amount":453.5454,"timestamp":1789589700294,"change":-0.0359,"changeRate":-0.000791,"amplitude":0},"volumeRatio":0.534406},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2757035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.534406,"shares":2757035,"dividePrice":0,"high":46.3649,"amplitude":0.00661,"preClose":45.3709,"low":46.065,"week52Low":27.8042,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":46.065,"eps":0,"divideRate":0,"volume":1225,"delay":0,"ttmEps":0,"open":46.095,"prevYearClose":36.6147,"prevWeekClose":45.3275,"prevMonthClose":45.79,"prevQuarterClose":45.2033,"fiveDayClose":45.371,"twentyDayClose":48.4384,"sixtyDayClose":42.604},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1168602224","title":"Cogent Biosciences宣佈FDA受理Bezuclastinib治療晚期系統性肥大細胞增多症的新藥申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1168602224","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168602224?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 20:01","pubTimestamp":1789473701,"startTime":"0","endTime":"0","summary":"Cogent Biosciences今日宣布，美国食品药品监督管理局已正式受理其针对Bezuclastinib的新药申请，该药物拟用于治疗晚期系统性肥大细胞增多症患者。因此，Cogent Biosciences此番取得的阶段性成果，无疑受到了医学界和投资圈的广泛关注。Bezuclastinib作为一种高选择性KIT D816V突变抑制剂，其设计初衷正是为了精准靶向驱动AdvSM等疾病的核心致病机制。随着NDA获得受理，后续的审评沟通及潜在的获批上市进程也将逐步展开，业界正持续跟踪该药物的监管动态与临床数据表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CANC","COGT","LFSC","BK4139","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103100254","title":"Guardant Health與Evernorth旗下Evicore達成協議，Shield血液檢測自2027年1月1日起納入結直腸癌篩查覆蓋範圍","url":"https://stock-news.laohu8.com/highlight/detail?id=1103100254","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103100254?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 04:08","pubTimestamp":1789416490,"startTime":"0","endTime":"0","summary":"Guardant Health公司宣布，Evernorth旗下的Evicore已决定将其Shield血液检测纳入结直肠癌（CRC）筛查的承保范围。这项覆盖计划将于2027年1月1日正式生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LFSC","GNMX","EKG","BK4588","BK4196","BK4535","LU0109394709.USD","PTH","GNOM","LU0320765992.SGD","GDOC","FFOX","BK4551","HELX","BK4585","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GNOM","SYNB","LU2322448791.USD","TMED","LFSC","HELX","LU1992135399.USD","PBE","BK4585","FTXH","BBH","CANC","LU2272731600.USD","LU2272731865.HKD","RSPH","PSCH","IBB","IDNA","IEIH","MRNY","XBIX","BK4588","FBT","BME","RXL","AZNH","LU2322448957.HKD","PJP","XPH","IEHS","LU2272731782.SGD","WDNA","IBRN","BIOY","LU2473716301.USD","IYH","MEDI","IE00B5TLWC47.USD","BBP","MRNX","LU1992135472.HKD","BIB","PPH","PBPH","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121233294","title":"Spyre Therapeutics旗下Spy003療法在第12周實現20%臨床緩解率及30%內鏡改善率","url":"https://stock-news.laohu8.com/highlight/detail?id=1121233294","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121233294?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:03","pubTimestamp":1788868991,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics日前宣布，其研发管线中的关键候选药物Spy003在临床试验中交出了令人瞩目的阶段性答卷。数据显示，在接受治疗满12周的时间节点上，该疗法成功促成了20%的患者达到临床缓解状态，与此同时，30%的受试者在内镜检查中观察到了显著的病情改善迹象。这一成果不仅彰显了Spy003在疾病修饰层面的潜在威力，也为公司后续的注册性临床推进注入了强劲信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":11,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/LFSC\",params:#limit:6,delay:false,,,undefined,":[]}}